Permanent Hypopituitarism Is Rare after Structural Traumatic Brain Injury in Early Childhood

Natasha L. Heather, Craig Jefferies, Paul L. Hofman, José G. B. Derraik, Christine Brennan, Patrick Kelly, James K. M. Hamill, Rhys G. Jones, Deborah L. Rowe, and Wayne S. Cutfield

Background: We sought to determine the incidence of permanent hypopituitarism in a potentially high-risk group: young children after structural traumatic brain injury (TBI).

Methods: We conducted a cross-sectional study with longitudinal follow-up. Dynamic tests of pituitary function (GH and ACTH) were performed in all subjects and potential abnormalities critically evaluated. Puberty was clinically staged; baseline thyroid function, prolactin, IGF-I, serum sodium, and osmolality were compared with age-matched data. Diagnosis of GH deficiency was based on an integrated assessment of stimulated GH peak (<5 µg/liter suggestive of deficiency), IGF-I, and growth pattern. ACTH deficiency was diagnosed based on a subnormal response to two serial Synacthen tests (peak cortisol <500 nmol/liter) and a metyrapone test.

Results: We studied 198 survivors of structural TBI sustained in early childhood (112 male, age at injury 1.7 ± 1.5 yr) 6.5 ± 3.2 yr after injury. Sixty-four of the injuries (33%) were inflicted and 134 (68%) accidental. Two participants had developed precocious puberty, which is within the expected background population rate. Peak stimulated GH was subnormal in 16 participants (8%), in the context of normal IGF-I and normal growth. Stimulated peak cortisol was low in 17 (8%), but all had normal ACTH function on follow-up. One participant had a transient low serum T₄. Therefore, no cases of hypopituitarism were recorded.

Conclusion: Permanent hypopituitarism is rare after both inflicted and accidental structural TBI in early childhood. Precocious puberty was the only pituitary hormone abnormality found, but the prevalence did not exceed that of the normal population. (J Clin Endocrinol Metab 97: 599–604, 2012)
The mechanism of traumatic hypopituitarism is proposed to be vascular. The pituitary gland is suspended on a stalk and potentially mobile. Long hypophyseal vessels traverse the stalk and supply the anterior pituitary via a latticework of portal vessels. These small perforating vessels may be vulnerable to shearing injury from sudden acceleration-deceleration forces. The pattern of anterior pituitary infarction, seen in up to a third of fatal head injuries, corresponds to areas supplied by portal vessels (13). Inflicted injuries can be caused by shaking or impact (or a combination of both), and either mechanism can produce identical pathological changes in the brain (14). The mechanisms by which inflicted TBI is produced, and the anatomy of the infant head and neck, may make infants particularly vulnerable to pituitary injury (14).

TBI is a heterogeneous condition, and current methods of grading are poorly predictive of pituitary dysfunction. The Glasgow Coma Scale (GCS) is widely used to define severity (15), although a variety of factors such as interval to hospital presentation, prehospital interventions, and limited interobserver reliability can affect scores (16, 17). Scoring preverbal children presents further difficulty (18), and a single score may be less meaningful after the repeated injury commonly seen in inflicted TBI (19). Structural TBI is likely to be a more robust way to define significant head injury, and therefore predict pituitary damage, in young children.

There are no robust studies examining the prevalence of hypopituitarism in children after TBI. Thus, we aimed to determine the prevalence of hypopituitarism in a potentially high-risk group: young children after structural TBI.

Assessments were performed at the Liggins Institute, University of Auckland. Height was measured to the nearest 0.1 cm using a Harpenden stadiometer. Pubertal staging was assessed as per Marshall and Tanner (22). Reported or measured parental heights were recorded. Height and height velocity scores (SDS) were derived from Tanner/Whitehouse reference data (22), and body mass index (BMI) SDS according to British 1990 standards (23).

Baseline fasting serum samples were taken for analysis of IGF-I, IGF-binding protein 3 (IGFBP-3), TSH, free T₄, free T₃, prolactin, sodium, and osmolality. Dynamic tests were used to evaluate GH and ACTH sufficiency. Clonidine (150 μg/m²) was administered orally and GH samples drawn at 0, +30, +60, +90, and +120 min. Intravenous arginine (6.5 ml/kg of 10% solution) was then administered and all additional samples drawn at +150 and +180 min. Low-dose Synacthen (1 μg as an iv push) was also given at baseline and cortisol measured at 0, +30, and +60 min. An additional gonadotropin stimulation test (GnRH, 100 μg) was performed in children with clinical evidence of precocious puberty, and LH and FSH measured at +30 and +60 min.

A Roche (Indianapolis, IN) E170 Modular laboratory analyzer using chemiluminescence was used for cortisol (coefficient of variation (CV) 6%), TSH (CV5%), free T₄ (CV 7%), and free T₃ (7%). A Roche Modular ISF laboratory analyzer measured serum sodium and serum osmolality. A Siemens Immulite 2000 (Siemens, Los Angeles, CA) using immunochromiluminescence was used for GH (CV 5%), IGF-I (CV 8%), prolactin (CV 5%), LH (CV 13%), and FSH (CV 12%). A Biocline RIA kit (Biocline, Marrickville, NSW, Australia) measured IGFBP-3 (CV 8%) and 11-deoxycortisol (CV 20%).

Hypopituitarism was defined as deficiency in one or more pituitary hormones. Baseline hormone values were compared with age-, sex-, and (where appropriate) pubertal stage-adjusted normal reference ranges provided by Auckland Healthcare Laboratory Services. All participants with abnormal results underwent further comprehensive review. The diagnosis of GH deficiency was based on the integrated assessment of stimulated GH peak, IGF-I, IGFBP-3, and growth parameters. Growth velocity was monitored over a minimum of 6 months among participants with peak stimulated GH below 5 μg/liter, which is New Zealand’s adopted cutoff for possible childhood GH deficiency based on current assay (24). Estrogen priming was reserved for repeat GH tests in prepubertal participants (ethinyl estradiol 40 μg/m² orally taken for 2 d before assessment). The diagnosis of ACTH deficiency was based on consistently subnormal results. Participants with peak stimulated cortisol below 500 nmol/liter underwent a second low-dose Synacthen test, and those with a second subnormal response underwent a short metyrapone test (oral metyrapone 30 mg/kg, maximum of 2 g, taken at 2300 h). Blood samples were obtained the following morning, and a normal response was defined as the sum of cortisol plus 11-deoxycortisol higher than 450 nmol/liter and ACTH higher than 20 pmol/liter (25). Possible precocious puberty was defined in girls as Tanner stage 2 breast development at under 8 yr or onset of menstruation at under 9.5 yr and in boys as testicular volume of at 4 ml or more at under 9 yr of age. Confirmation was obtained via pubertal level of sex steroids and stimulated LH peak higher than 10 IU/liter.

Data are presented as mean ± SD. Two-tailed χ² tests with Yates correction were used to assess whether the frequency of precocious puberty among boys and girls who suffered TBI was greater than normal, based on reference data from the Danish national database (26). This study was approved by the hospital (Auckland District Health Board) and regional (Northern X) ethics committees.

Subjects and Methods

Starship Children’s Hospital is the only hospital in New Zealand with a dedicated pediatric intensive care unit as well as being the regional neurosurgical pediatric center for the Auckland region. Admissions after accidental or inflicted TBI were identified from both the Hospital’s Trauma (2000–2010) and Child Protection (1992–2010) databases. Cases were eligible if structural TBI had occurred within the first 5 yr of life and more than 12 months previously. Structural TBI was defined as the presence of skull fracture, intracranial hemorrhage (extradural, subdural, subarachnoid, or intraventricular), or cerebral injury (contusion, infarct, edema, or diffuse axonal injury) reported on computerized tomography or magnetic resonance imaging scan. Exclusion criteria were death during or after admission, residence outside of New Zealand, age under 3 yr at assessment, or pituitary dysfunction that predated TBI.

All children with inflicted TBI met the following criteria: structural TBI, injuries incompatible with the history (20), careful evaluation by the multidisciplinary child protection team, and notification to the statutory authorities. Functional TBI severity was assessed as per GCS (15), whereas structural TBI was graded according to the Abbreviated Injury Scale (21).
Mass evacuation or drain inserted.

Results

This study identified 770 TBI admissions of children under 5 yr of age. A total of 156 children had no structural TBI, 42 were deceased, and an additional 127 were excluded due to either young age or geographical distance from the testing center. A total of 175 could not be contacted, and 270 were invited to participate. Sixty-seven declined, the most common reason being no concern about the child’s health or development. Five others were excluded because secure venous access could not be obtained. As a result, 198 participants were studied, whose baseline characteristics are outlined in Table 1.

Sixty-four participants (32%) sustained inflicted and 134 (68%) accidental TBI. Computerized tomography reports were available for all but three participants and magnetic resonance imaging scans for 34%. Intracerebral hemorrhage (66%), cerebral injury (66%), and skull fractures (70%) occurred in most. Most subjects had severe to critical structural TBI, although just under half had moderate to severe injury by GCS (Table 1). Specific pituitary abnormality (posterior hemorrhage) was reported in only one case and was associated with transient diabetes insipidus. Average length of stay in hospital was 10.5 d, and 40% were admitted to intensive care (Table 1).

Endocrine evaluation

Patients were assessed 6.5 ± 3.2 yr after injury, at an age of 8.3 ± 3.3 yr. A total of 170 participants (85%) were Tanner stage 1–2, 22 (11%) stage 3–4, and six (3%) stage 5. Chronic illness included asthma (eight participants reported taking low-dose inhaled steroids), medically treated ADHD, congenital cardiac disease, and achondroplasia (height SDS −4.8, omitted from auxological analysis). Endocrine assessment was complete in 191; four participants declined GH stimulation tests, and one additionally declined the Synacthen test. Thyroid function was not available in three cases.

GH-IGF-I axis

Peak GH response to arginine-clonidine was 14.4 ± 7.8 μg/liter. GH peak was under 10 μg/liter in 65 subjects (33%) and under 5 μg/liter in 16 (8%). Among subjects with GH under 5 μg/liter (with apparent GH deficiency), mean height SDS was 1.0 ± 1.2 and BMI SDS 2.8 ± 0.8, whereas both IGF-I and IGFBP-3 were within the normal range for all subjects (Table 2). This group was followed in growth clinics for a period of 6–36 months, and all demonstrated normal height velocity (Table 2). Repeat arginine-clonidine tests were performed in five cases. Repeat GH was more than 5 μg/liter in all but one case, likely confounded by severe obesity (BMI SDS 4.2). None of the subjects with short stature or who were short for their parents’ heights had low GH or IGF-I levels. There were six subjects (3%) who had height below −2 SDS at assessment and seven (4%) with height corrected for genetic potential below −2 SDS. Only two subjects had short stature as assessed by both measures: one with achondroplasia and another with spastic quadriplegia.

ACTH axis

Basal cortisol was 270 ± 150 nmol/liter and peak 695 ± 152 nmol/liter. Suboptimal cortisol response (<500 nmol/liter) was seen in 17 (9%) participants (range 304–487 nmol/liter). None of these had hypotension, fasting hypoglycemia, or postural hypotension suggestive of adrenal insufficiency. Three reported regular low-dose inhaled steroids. Interim stress steroid precautions were advised in all cases. All 17 underwent repeat Synacthen tests, 13 of which achieved peak cortisol above target. Four remained low, one declined additional assessment (peak cortisol 490 nmol/liter), and three responded appropriately to metyrapone. None were considered to have significant ACTH deficiency.
Precocious puberty

One male aged 7 yr had previously been diagnosed with precocious puberty (Tanner G3P3 with 6- to 8-ml testes, stimulated LH peak 21.4 IU/liter, testosterone 8.9 nmol/liter, and bone age +2 SDS), and was treated with regular depot injections of leuprorelin acetate. One female was diagnosed with precocious puberty at the time of assessment, with a history of breast development at 5–6 yr and menses from 7.5 yr. She had been seen by her general practitioner and reassessed that her pubertal development was normal. At 8 yr, she had been off treatment and asymptomatic for 3 yr at the time of assessment. Seven subjects had mildly elevated prolactin levels (range 370–750 mIU/liter) that were not considered clinically significant. In one case, this was attributed to risperidone, and repeat prolactin was normal in all three cases where it was reassessed.

Discussion

We show that permanent hypopituitarism is rare after structural TBI in early childhood in the largest such pediatric study performed to date. There were two cases of precocious puberty, but the prevalence did not exceed that of the normal childhood population. All other apparent pituitary hormone deficiencies were shown to be erroneous, when tests were repeated or considered as part of comprehensive assessments.

Importantly, there were no cases of GH deficiency. This finding contrasts to high rates reported by many previous TBI studies, showing a prevalence of 11–31% among adults (27–30) and 16–42% in small pediatric studies (5, 7, 10). Whereas earlier studies have based the diagnosis of GH deficiency entirely on GH stimulation tests, we performed detailed assessments of GH, IGF-I, and growth pattern, with recognition of obesity.

Using provocative GH tests alone and conservative international criteria (peak GH <10 μg/liter) (31), up to 33% of our study population might have been incorrectly diagnosed with GH deficiency. All these subjects were overweight or obese but had normal height, height velo-

### TABLE 2. Hormonal and growth profile of study participants with GH peak under 5 μg/liter

<table>
<thead>
<tr>
<th>Subject</th>
<th>Gender</th>
<th>Age (yr)</th>
<th>Tanner stage</th>
<th>GH peak (μg/liter)</th>
<th>IGF-I (μg/ml)</th>
<th>Height (cm)</th>
<th>Height SDS</th>
<th>BMI (kg/m&lt;sup&gt;2&lt;/sup&gt;)</th>
<th>BMI SDS</th>
<th>HV (cm/yr)</th>
<th>HV SDS</th>
<th>HV interval (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GH1</td>
<td>F</td>
<td>14</td>
<td>5</td>
<td>2.0 (6)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>385</td>
<td>167.8</td>
<td>1.0</td>
<td>30.2</td>
<td>2.5</td>
<td>ND&lt;sup&gt;b&lt;/sup&gt;</td>
<td>ND&lt;sup&gt;b&lt;/sup&gt;</td>
<td>ND&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>GH2</td>
<td>M</td>
<td>8</td>
<td>1</td>
<td>2.1 (8.6)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>134</td>
<td>134</td>
<td>1.5</td>
<td>30.4</td>
<td>3.8</td>
<td>6.8</td>
<td>1.6</td>
<td>9</td>
</tr>
<tr>
<td>GH3</td>
<td>M</td>
<td>7</td>
<td>1</td>
<td>2.2 (5.6)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>100</td>
<td>122</td>
<td>1.0</td>
<td>23.9</td>
<td>3.1</td>
<td>4.7</td>
<td>7.4</td>
<td>0.8</td>
</tr>
<tr>
<td>GH4</td>
<td>M</td>
<td>12</td>
<td>1</td>
<td>2.3</td>
<td>144</td>
<td>159</td>
<td>1.2</td>
<td>34.5</td>
<td>3.4</td>
<td>8.5</td>
<td>2.9</td>
<td>6</td>
</tr>
<tr>
<td>GH5</td>
<td>F</td>
<td>9</td>
<td>1</td>
<td>2.3</td>
<td>123</td>
<td>131</td>
<td>2.3</td>
<td>30.8</td>
<td>3.5</td>
<td>7.6</td>
<td>2.8</td>
<td>6</td>
</tr>
<tr>
<td>GH6</td>
<td>F</td>
<td>6</td>
<td>1</td>
<td>3.0</td>
<td>143</td>
<td>124</td>
<td>1.3</td>
<td>25.6</td>
<td>3.3</td>
<td>7.2</td>
<td>2.1</td>
<td>36</td>
</tr>
<tr>
<td>GH7</td>
<td>M</td>
<td>7</td>
<td>1</td>
<td>3.1</td>
<td>127</td>
<td>128</td>
<td>0.5</td>
<td>24.4</td>
<td>3.1</td>
<td>5.9</td>
<td>0.6</td>
<td>17</td>
</tr>
<tr>
<td>GH8*</td>
<td>F</td>
<td>8</td>
<td>4</td>
<td>3.4 (7.6)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>240</td>
<td>124</td>
<td>0.9</td>
<td>26.5</td>
<td>2.9</td>
<td>3.9</td>
<td>2.1</td>
<td>8</td>
</tr>
<tr>
<td>GH9</td>
<td>F</td>
<td>10</td>
<td>1</td>
<td>3.8</td>
<td>206</td>
<td>139</td>
<td>0.1</td>
<td>20.8</td>
<td>1.3</td>
<td>4.9</td>
<td>0.5</td>
<td>12</td>
</tr>
<tr>
<td>GH10</td>
<td>M</td>
<td>11</td>
<td>1</td>
<td>4.6</td>
<td>143</td>
<td>163.3</td>
<td>2.3</td>
<td>26.5</td>
<td>2.6</td>
<td>4.9</td>
<td>0.1</td>
<td>6</td>
</tr>
<tr>
<td>GH11</td>
<td>M</td>
<td>7</td>
<td>1</td>
<td>4.6</td>
<td>142</td>
<td>132</td>
<td>0.8</td>
<td>23.9</td>
<td>2.8</td>
<td>5.5</td>
<td>0.1</td>
<td>36</td>
</tr>
<tr>
<td>GH12</td>
<td>F</td>
<td>8</td>
<td>1</td>
<td>4.7</td>
<td>196</td>
<td>132</td>
<td>0.6</td>
<td>22.3</td>
<td>2.2</td>
<td>5.9</td>
<td>0.6</td>
<td>12</td>
</tr>
<tr>
<td>GH13</td>
<td>M</td>
<td>6</td>
<td>1</td>
<td>4.8 (4.2)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>151</td>
<td>139.5</td>
<td>3.6</td>
<td>29.6</td>
<td>4.2</td>
<td>5.9</td>
<td>0.2</td>
<td>6</td>
</tr>
<tr>
<td>GH14</td>
<td>M</td>
<td>6</td>
<td>1</td>
<td>4.8</td>
<td>231</td>
<td>123</td>
<td>1.4</td>
<td>19.2</td>
<td>2.2</td>
<td>6.1</td>
<td>0.1</td>
<td>7</td>
</tr>
<tr>
<td>GH15</td>
<td>M</td>
<td>10</td>
<td>1</td>
<td>4.9</td>
<td>221</td>
<td>140</td>
<td>0.1</td>
<td>22.9</td>
<td>2.2</td>
<td>5.5</td>
<td>0.1</td>
<td>18</td>
</tr>
<tr>
<td>GH16</td>
<td>M</td>
<td>12</td>
<td>1</td>
<td>4.9</td>
<td>180</td>
<td>157.3</td>
<td>1.2</td>
<td>23.8</td>
<td>2.2</td>
<td>5.5</td>
<td>0.8</td>
<td>6</td>
</tr>
</tbody>
</table>

F, Female; HV, height velocity; M, male.

<sup>a</sup> Values in parentheses refer to repeat arginine-clonidine GH tests, sex-steroid priming used for subjects GH2, GH3, and GH13.

<sup>b</sup> No data (ND) because subject GH1 had reached final adult height before the study.

<sup>c</sup> Subject GH8 has spastic quadriplegia with flexion contractures as well as precocious puberty and advanced bone age (+3 SDS), which collectively are growth limiting independently of GH status.
ity, and IGF-I level. It is common for normally growing children to display low GH responses that may falsely suggest deficiency (32). Stimulated GH levels are inversely associated with BMI in childhood (33), and misleadingly low GH levels (suggestive of deficiency) are especially common in obese children. Nonetheless, previous childhood TBI studies have not adjusted for confounding adiposity. In addition, GH tests are poorly reproducible; individuals who undergo repeated tests have highly variable results (34). In our study, 80% of low GH responses were normal when tests were repeated, and the remainder had normal IGF-I and growth velocity. Similarly, in contrast to what is usually reported in TBI studies, we found no cases of ACTH deficiency: 5–27% for adults (27–30) and 18–34% for children (5, 7, 10). Once again, retesting of subnormal ACTH results showed that these were false positives (i.e. apparent ACTH deficiency in normal children).

Given the high-risk group we studied, it is surprising that we observed no cases of hypopituitarism. Young children are thought to be particularly vulnerable to the effects of acceleration-deceleration on the brain and cerebral vasculature (14). Our study population was a clearly defined homogeneous group of young children with structural TBI. It was apparent within our cohort that significant structural injury can be associated with mild GCS impairment. The relationship between TBI severity as defined by GCS and hypopituitarism has been weak and may reflect the indirect nature of GCS as an assessment tool for pituitary damage. In addition, a high-risk subgroup was included, children after inflicted TBI. Inflicted brain injuries are typically repeated and severe and affect very young infants, yet no hypopituitarism was found. Note that these findings may not be applicable to adolescents, whose physical characteristics and types of injury more closely resemble those seen in adults.

Our data on precocious puberty were within the expected prevalence for girls. There was a trend toward a significant increase for boys, although this was also within the expected range. The population prevalence of precocious puberty is not well described, and our reference data were derived from the Danish national registry (26). The authors stressed that their estimates were conservative, particularly because they relied upon referrals to pediatricians. The pathogenic mechanism of precocious puberty is loss of normal childhood hypothalamic inhibition of pituitary gonadotropins and could be anticipated to increase after TBI. However, our study shows that the rate of precocious puberty after TBI is unlikely to exceed that of the normal population. Nonetheless, not all subjects in our study had reached the normal age of pubertal onset, so that our prevalence data might also have been an underestimate. Thus, although precocious puberty appears to be rare after TBI, prevalence should ideally be assessed by longitudinal follow-up of a large population.

The major challenge for this study was recruitment, mostly due to difficulty in obtaining up-to-date case contact details. This was particularly challenging among children with inflicted injuries and as the interval from TBI increased. Overall, the rate of acceptance among those contacted was high (75%), with probable selection bias toward children with chronic disability, who would be expected to be at greater risk of hypopituitarism. Another potential limitation was the variable timing of assessments. However, because the purpose of this study was to assess the rate of permanent pituitary hormone deficiency, all assessments were performed at least 1 yr after injury (beyond which point the occurrence of new hypopituitarism is rare) (35). It is possible that some of our subjects had already recovered from transient hormone deficiency, but the significance of this would be unclear.

In conclusion, permanent hypopituitarism after TBI appears to be a very rare event. Given that all subjects with initial tests suggestive of ACTH deficiency were normal when reassessed, significant abnormality that would require treatment is likely to be rare, but further evaluation of ACTH status within a larger cohort will help to clarify this issue. In our cohort, precocious puberty was the only pituitary abnormality present. We found no cases of GH deficiency that met comprehensive assessment criteria, even though it is generally reported to be common after TBI. Because both precocious puberty and GH deficiency can be detected on clinical assessment during childhood, a pragmatic approach would be for family physicians to monitor growth and development in children after TBI. Invasive assessments should be reserved for selected cases where there is slow growth or other clinical suspicion of hypopituitarism.

Acknowledgments

We thank participants and our advisory Kaitiaki group. We also thank Rangi Dansey for his assistance with the Starship Trauma database and Andrew Law for his input in planning the study.

Address all correspondence and requests for reprints to: Wayne S. Cutfield, Liggins Institute, University of Auckland, Private Bag 92019, Auckland, New Zealand. E-mail: w.cutfield@auckland.ac.nz.

The study was supported by grants from the Health Research Council of New Zealand and the Australasian Pediatric Endocrine Group. N.L.H. was supported by the Starship Fellowship Foundation.

N.L.H. and W.S.C. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Disclosure Summary: All authors and respective spouses, partners, or children have no financial or non-financial interests to declare that may be relevant to this submitted work.

References

24. Barth JH, Sibley PEC 2008 Standardization of the IMMULITE system growth hormone assay with the recombinant is 98/574. Ann Clin Biochem 45:598–600